AlexanderLesokhin MD
@LesokhinMD
Followers
3K
Following
266
Statuses
408
I am an oncologist @sloan_kettering who specializes in immunotherapy and the treatment of multiple myeloma. Tweets are mine.
New York, NY
Joined March 2013
RT @UrviShahMD: This project has been a wonderful collaboration & team science including @DrMvandenBrink @vandenBrinkLab @LesokhinMD @szusm…
0
11
0
RT @MalinHultcrantz: Colesevelam is highly effective and safe for treatment of lenalidomide associated diarrhea: - Phase 2 trial, 25 pts -…
0
14
0
@MSKCancerCenter @AbdelWahablab Congrats Omar! Well deserved!! #ASH2023 (Anyone else curious about the music choice?)
1
0
2
@NBahlis @NatureMedicine @hollyleeYJ @FrancescoMaura4 @RascheLeo @PedalheadPHX @UCalgary @UCalgaryMed @Charb_Cancer Superb paper!
0
0
4
RT @Mohty_EBMT: Thank you all for this smooth and important collaboration that lead to the approval of elranatamab by FDA @NatureMedicine @…
0
49
0
RT @SaheliSadanand: 🌟Hot off the press in @NatureMedicine! The pivotal phase 2 MagnetisMM-3 trial of #Elranatamab in patients with r/r #Mul…
0
5
0
RT @szusmani: Congratulations @LesokhinMD @NoopurRajeMD and all colleagues involved with the studies #mmsm
0
3
0
Another exciting approval for MM patients! Honored to have been a part from FIH to approval @MSKHemOncTrials. @MSKCancerCenter. Pfizer’s ELREXFIO™ Receives U.S. FDA Accelerated Approval for Relapsed or Refractory Multiple Myeloma | Pfizer
2
11
52
U.S. FDA Approves TALVEY™ (talquetamab-tgvs), a First-in-Class Bispecific Therapy for the Treatment of Patients with Heavily Pretreated Multiple Myeloma
0
0
5
RT @NoopurRajeMD: Sharing our consensus on this important topic @BloodCancerJnl @SagarLonialMD @mvmateos : Monitoring, prophylaxis, and tre…
0
26
0
RT @UrviShahMD: Congratulations @kordeneha1 on presenting patient centric data from the maintenance cessation study in myeloma showing 12 m…
0
9
0
@calliecoombsmd Reminds me of when a patient said this to the fellow entering his room on rounds. Then the attending walked in (me) and the patient said, “oh! Ok”. Enjoy it while it lasts!
0
0
4
RT @ESmithMDPhD: Our report of first-in-human GPRC5D-targeted CAR T cells for MM is out in NEJM! The trial was led by Sham Mailankody and c…
0
138
0
0
0
2